Single User License
INR 129860
Site License
INR 259720
Corporate User License
INR 389580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2015

Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2015


  • Products Id :- GMDHC6999IDB
  • |
  • Pages: 96
  • |
  • August 2015
  • |
  • |
  Request for Sample Report

Executive Summary

Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Uterine Leiomyoma (Uterine Fibroids)-Pipeline Review, H2 2015', provides an overview of the Uterine Leiomyoma (Uterine Fibroids)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Uterine Leiomyoma (Uterine Fibroids) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Uterine Leiomyoma (Uterine Fibroids) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Uterine Leiomyoma (Uterine Fibroids) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Uterine Leiomyoma (Uterine Fibroids) Overview 8

Therapeutics Development 9

Pipeline Products for Uterine Leiomyoma (Uterine Fibroids)-Overview 9

Pipeline Products for Uterine Leiomyoma (Uterine Fibroids)-Comparative Analysis 10

Uterine Leiomyoma (Uterine Fibroids)-Therapeutics under Development by Companies 11

Uterine Leiomyoma (Uterine Fibroids)-Therapeutics under Investigation by Universities/Institutes 12

Uterine Leiomyoma (Uterine Fibroids)-Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Uterine Leiomyoma (Uterine Fibroids)-Products under Development by Companies 16

Uterine Leiomyoma (Uterine Fibroids)-Products under Investigation by Universities/Institutes 17

Uterine Leiomyoma (Uterine Fibroids)-Companies Involved in Therapeutics Development 18

AbbVie Inc. 18

Addex Therapeutics Ltd 19

Bayer AG 20

BioSpecifics Technologies Corp. 21

Dongkook Pharmaceutical Co., Ltd. 22

Euroscreen S.A. 23

Kissei Pharmaceutical Co., Ltd. 24

Laboratoire HRA Pharma 25

Novartis AG 26

Repros Therapeutics Inc. 27

Takeda Pharmaceutical Company Limited 28

Uterine Leiomyoma (Uterine Fibroids)-Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

collagenase clostridium histolyticum-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Drug to Activate Progesterone Receptor for Uterine Fibroids-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Drug to Antagonize GnRH Receptor for Endometriosis and Uterine Leiomyoma-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Drugs for Endometriosis and Uterine Fibroids-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

elagolix sodium-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

ESN-364-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

EVE-104-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

KLH-2109-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

LFA-102-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

relugolix-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Small Molecule to Antagonize FSH Receptor for Women's Health-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

telapristone acetate-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

triptorelin pamoate-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

ulipristal acetate-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

vilaprisan-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

VPE-001-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

VPEA-004-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

Uterine Leiomyoma (Uterine Fibroids)-Recent Pipeline Updates 62

Uterine Leiomyoma (Uterine Fibroids)-Dormant Projects 83

Uterine Leiomyoma (Uterine Fibroids)-Dormant Projects 83

Uterine Leiomyoma (Uterine Fibroids)-Discontinued Products 84

Uterine Leiomyoma (Uterine Fibroids)-Product Development Milestones 85

Featured News & Press Releases 85

Mar 27, 2013: Neurocrine Biosciences Initiates Phase IIb Study Of Elagolix For Treatment Of Uterine Fibroids 85

Feb 28, 2013: Repros Announces FDA Grants End Of Phase II Meeting To Discuss Proellex-V Phase III Study Design 85

Jan 03, 2013: Repros Reports Positive Topline Results From Phase II Study Of Proellex-V For Treatment Of Uterine Fibroids 85

Jul 30, 2012: FDA Schedules Meeting With Repros To Discuss Phase II Protocol For Proellex For Treatment Of Endometriosis 87

Jul 23, 2012: Repros's Proellex-V Shows Consistent Efficacy In Phase II Study Of Uterine Fibroids 87

Apr 30, 2012: Repros's Proellex-V Clears Hurdle In Uterine Fibroid Program 88

Mar 12, 2012: Watson Initiates US Phase III Clinical Trial Of Esmya 89

Feb 27, 2012: HRA Pharma's Esmya Receives European Commission Marketing Authorization For Pre-Operative Treatment Of Uterine Fibroids 90

Feb 02, 2012: PregLem Announces Full Results Of PEARL I And II Studies Of Esmya Published In New England Journal Of Medicine 91

Jan 04, 2012: FDA Accepts Repros's Investigational New Drug Application For Proellex-V For Treatment Of Uterine Fibroids 92

Appendix 95

Methodology 95

Coverage 95

Secondary Research 95

Primary Research 95

Expert Panel Validation 95

Contact Us 95

Disclaimer 96

List of Tables

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2015 9

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids)-Comparative Analysis, H2 2015 10

Number of Products under Development by Companies, H2 2015 11

Number of Products under Investigation by Universities/Institutes, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 13

Comparative Analysis by Clinical Stage Development, H2 2015 14

Comparative Analysis by Early Stage Development, H2 2015 15

Products under Development by Companies, H2 2015 16

Products under Investigation by Universities/Institutes, H2 2015 17

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by AbbVie Inc., H2 2015 18

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Addex Therapeutics Ltd, H2 2015 19

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Bayer AG, H2 2015 20

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by BioSpecifics Technologies Corp., H2 2015 21

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015 22

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Euroscreen S.A., H2 2015 23

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2015 24

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Laboratoire HRA Pharma, H2 2015 25

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Novartis AG, H2 2015 26

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Repros Therapeutics Inc., H2 2015 27

Uterine Leiomyoma (Uterine Fibroids)-Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 28

Assessment by Monotherapy Products, H2 2015 29

Number of Products by Stage and Target, H2 2015 31

Number of Products by Stage and Mechanism of Action, H2 2015 33

Number of Products by Stage and Route of Administration, H2 2015 35

Number of Products by Stage and Molecule Type, H2 2015 37

Uterine Leiomyoma (Uterine Fibroids) Therapeutics-Recent Pipeline Updates, H2 2015 62

Uterine Leiomyoma (Uterine Fibroids)-Dormant Projects, H2 2015 83

Uterine Leiomyoma (Uterine Fibroids)-Discontinued Products, H2 2015 84

List of Figures

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2015 9

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids)-Comparative Analysis, H2 2015 10

Number of Products under Development by Companies, H2 2015 11

Comparative Analysis by Clinical Stage Development, H2 2015 14

Comparative Analysis by Early Stage Products, H2 2015 15

Assessment by Monotherapy Products, H2 2015 29

Number of Products by Top 10 Targets, H2 2015 30

Number of Products by Stage and Top 10 Targets, H2 2015 30

Number of Products by Top 10 Mechanism of Actions, H2 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 32

Number of Products by Top 10 Routes of Administration, H2 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 34

Number of Products by Top 10 Molecule Types, H2 2015 36

Number of Products by Stage and Top 10 Molecule Types, H2 2015 36

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AbbVie Inc.

Addex Therapeutics Ltd

Bayer AG

BioSpecifics Technologies Corp.

Dongkook Pharmaceutical Co., Ltd.

Euroscreen S.A.

Kissei Pharmaceutical Co., Ltd.

Laboratoire HRA Pharma

Novartis AG

Repros Therapeutics Inc.

Takeda Pharmaceutical Company Limited

Uterine Leiomyoma (Uterine Fibroids) Therapeutic Products under Development, Key Players in Uterine Leiomyoma (Uterine Fibroids) Therapeutics, Uterine Leiomyoma (Uterine Fibroids) Pipeline Overview, Uterine Leiomyoma (Uterine Fibroids) Pipeline, Uterine Leiomyoma (Uterine Fibroids) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com